Cell Medica Announces Appointment of Industry Leader Dr Annalisa Jenkins as Chair

LONDON & HOUSTON, Texas–(BUSINESS WIRE)–Cell Medica (or ‘the Company’), a leader in next generation cellular
immunotherapies for the treatment of cancer, today announced the
appointment of Annalisa Jenkins, MBBS, FRCP, as Chair of the Board of
Directors.

Dr Annalisa Jenkins is a life sciences business and thought leader with
over 25 years of biopharmaceutical industry experience in advancing
programs from scientific research through clinical development,
regulatory approval and into healthcare systems globally. Prior to
joining Cell Medica, Dr Jenkins served as President and CEO of Dimension
Therapeutics, a leading gene therapy company that was acquired by
Ultragenyx Pharmaceutical in November 2017. Dr Jenkins previously held
multiple leadership positions, including executive vice president, head
of Global Research and Development for Merck Serono, where she led
Global Medical Affairs and Quality and was a member of Merck Serono’s
Pharmaceutical Executive Committee. Prior to this, Dr Jenkins had a
successful 14-year career at Bristol-Myers Squibb (BMS), attaining the
role of senior vice president and head of Global Medical Affairs. During
her tenure at BMS, Dr Jenkins played a key role in the development,
approval, and/or commercialisation of products in multiple therapeutic
areas, including immuno-oncology, cardiology, immunology and infectious
diseases.

Earlier in her career, Dr Jenkins was a medical officer in the British
Royal Navy during the Gulf Conflict, achieving the rank of Surgeon
Lieutenant Commander. Dr Jenkins graduated with a degree in medicine
from St. Bartholomew’s Hospital, University of London and subsequently
trained in cardiovascular medicine in the U.K. National Health Service.

Dr Jenkins is a board member of several growing companies and a member
of the Science Board to the U.S. Food & Drug Administration (FDA). She
also serves on the board of the Center for Talent Innovation in the U.K.

Gregg Sando, CEO of Cell Medica, commented:

“We are very pleased to have Annalisa join Cell Medica as we move
forward with our next generation cellular immunotherapies for the
treatment of cancer. Her deep understanding and thought leadership in
immuno-oncology drug development, as well as her board and executive
leadership experience with innovative biotechnology companies, make
Annalisa exceptionally well-qualified to serve as Chair of Cell Medica’s
Board.”

“I would like to thank Dr Thomas Hecht for his seven years as
Chairman of Cell Medica during which we have had to manage the company
through the rapidly changing dynamics driving the cellular immunotherapy
business. We are delighted that Thomas will remain on the Board as a
much-valued member of the team.”

Dr Annalisa Jenkins commented:

“The cell-based immunotherapy industry has come of age in 2017 with
the first marketing approvals and a growing pipeline of exciting
products in late stage development that address current patient unmet
needs and gaps with available therapeutics. With a portfolio of
differentiated and powerful technology platforms, including both
chimeric antigen receptors (CARs) and engineered T cell receptors
(TCRs), Cell Medica is very well positioned to address these unmet needs
and make a significant impact for cancer patients globally. I look
forward to assisting the Company in developing and delivering the
potential of its transformative cell-based immunotherapies.”

– ENDS –

Notes to Editors

About Cell Medica

Cell Medica is committed to transforming patients’ lives through
developing the significant therapeutic potential of cellular
immunotherapy for the treatment of cancer. We are advancing innovative
cell-based therapies using proprietary technology platforms
incorporating chimeric antigen receptors (CARs) and engineered T cell
receptors (TCRs). Our CAR-modified T cell products are being developed
in collaboration with Baylor College of Medicine and University of North
Carolina. Cell Medica’s differentiated approach utilises NKT cells (a
subset of T cells) engineered to express IL-15 to maintain cytotoxic
function within the immunosuppressive microenvironment. Our CAR pipeline
includes a unique off-the-shelf allogeneic product aimed at CD19 B cell
lymphomas. In the field of engineered TCRs, our Dominant TCR platform
technology, developed at University College London, improves the potency
of TCR-modified T cells while maintaining the safety profile. Other
technologies in our portfolio include the utilisation of EBV-specific T
cells for the treatment of lymphomas associated with the Epstein Barr
virus. Cell Medica is headquartered in London with subsidiaries in
Zurich and Houston.

Contacts

Cell Medica
Gregg Sando, CEO
+44 (0)20 7554 4070
Gregg.Sando@cellmedica.co.uk